The role of the third-generation oral cephalosporin cefditoren pivoxil in the treatment of community-acquired infection in adults;Situación de la cefalosporina oral de tercera generación cefditoreno pivoxil en el tratamiento de la infección comunitaria del adulto

Revista Espanola de Quimioterapia

Volumn 18, Issue 3, 2005, Pages 210-216

  Gimenez M J ^a   Gomez Lus M L ^a   Valdes L ^b   Aguilar, L ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b GLAXOSMITHKLINE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFDITOREN; CEFDITOREN PIVOXIL; CEFOTAXIME; CEFUROXIME; CEPHALOSPORIN; CLARITHROMYCIN; LEVOFLOXACIN; PENICILLIN G;

ANTIBIOTIC RESISTANCE; COMMUNITY ACQUIRED PNEUMONIA; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; MORAXELLA CATARRHALIS; REVIEW; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ADMINISTRATION, ORAL; ADULT; BACTERIAL INFECTIONS; CEFTIZOXIME; COMMUNITY-ACQUIRED INFECTIONS; HUMANS;

EID: 28844489414     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Llor, C. Consideraciones a la hora de la prescripción antibiótica en atención primaria. Med Clin Monogr (Barc) 2004; 5: 52-57.
2. Mogyoros, M. Challenges of managed care organisations in treating respiratory tract infections in an age of antibiotic resistance. Am J Man Care 2001; 7 (Suppl. 6): 163-169.
3. Huovinen, P., Cars, O. Control of antimicrobial resistance: Time for action. The essentials of control are already well known. BMJ 1998; 317: 613-614.
4. Libro Blanco. Problemática de las infecciones urinarias en España. Ed. Liade, Madrid 1989; 19 y 52.
5. García-Rey, C., Fenoll, A., Aguilar, L., Casal, J. Effect of social and climatological factors on antimicrobial use and Streptococcus pneumoniae resistance in different provinces in Spain. J Antimicrob Chemother 2004; 54: 465-471.
6. Granizo, J.J., Aguilar, L., Casal, J., García-Rey, C., Dal-Ré, R., Baquero, F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). J Antimicrob Chemother 2000; 46: 767-773.
7. García-Rey, C., Aguilar, L., Baquero, F., Casal, J., Dal-Ré, R. Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. J Clin Microbiol 2002; 40: 159-164.
8. Gómez, J., Ruiz-Gómez, J., Hernández-Cardona, J.L., Nuñez, M.L., Canteras, M., Valdés, M. Antibiotic resistance patterns of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: A prospective study in Murcia, Spain, 1983-1992. Chemotherapy 1994; 40: 299-303.
9. Nissinen, A., Gronroos, P., Huovinen, P. y cols. Development of beta-lactamase-mediated resistance to penicillin in middle-ear isolates of Moraxella catarrhalis in Finnish children, 1978-1993. Clin Infect Dis 1995; 21: 1193-1196.
10. Granizo, J.J., Aguilar, L., Casal, J., Dal-Ré, R., Baquero, F. Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). J Antimicrob Chemother 2000; 46: 959-964.
11. García-Rey, C., Aguilar, L., Baquero, F., Casal, J., Martín, J.E. Pharmacoepidemiological analysis of provincial differences between consumption of macrolides and rates of erythromycin resistance among Streptococcus pyogenes isolates in Spain. J Clin Microbiol 2002; 40: 2959-2963.
12. Ena, J., López-Perezagua, M.M., Martínez-Peinado, C., Cia-Barrio, M.A., Ruiz-López, I. Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones. Diagn Microbiol Infect Dis 1998; 30: 103-107.
13. Pérez-Trallero, E., García de la Fuente, C., García-Rey, C. y cols., Spanish Surveillance Group for Respiratory Pathogens. Geographical and ecological analysis of resistance, coresistance and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-1972.
14. Clinical and Laboratory Standards Institute/NCCLS. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. CLSI/NCCLS document M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA, USA, 2005.
15. Soriano, F., Granizo, J.J., Fenoll, A. y cols. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four Southern European countries (ARISE Project) from adult patients: Results from the Cefditoren Surveillance Program. J Chemother 2003; 15: 107-112.
16. Morosini, M.I., Cantón, R., Loza, E. y cols. In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms. Antimicrob Agents Chemother 2001; 45: 2427-2431.
17. Buxbaum, A., Forsthuber, S., Graninger, W., Georgopoulos, A. Comparative activity of telithromycin against typical community-acquired respiratory pathogens. J Antimicrob Chemother 2003; 52: 371-374.
18. Morosini, M.I., Cantón, R., Loza, E., del Campo, R., Almaraz, F., Baquero, F. Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: In vitro activities of telithromycin and cethromycin. J Antimicrob Chemother 2003; 52: 50-55.
19. Andreu, A., Alós, J.I., Gobernado, M., Marco, F., de la Rosa, M., García-Rodríguez, J.A., Grupo Cooperative Español para el Estudio de la Sensibilidad Antimicrobiana de los Patógenos Urinarios. Etiología y sensibilidad a los antimicrobianos de los uropatógenos causantes de la infección urinaria baja adquirida en la comunidad. Estudio national multicéntrico. Enferm Infecc Microbiol Clin 2005; 23: 4-9.
20. Jacobs, M.R. How can we predict bacterial eradication? Int J Infect Dis 2003; 7 (Suppl. 1): S13-20.
21. Soriano, F. Importancia de los parámetros farmacocinéticos y farmacodinámicos en la elección del tratamiento antimicrobiano de la infección respiratoria. Med Clin Monogr (Barc) 2004; 5: 6-11.
22. Gattringer, R., Urbauer, E., Traunmuller, F. y cols. Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers. Antimicrob Agents Chemother 2004; 48: 4650-4653.
23. Aguado-García, J.M., Martín-Herrero, J.E., Lumbreras-Bermejo, C. Resistencias bacterianas y farmacodinámica como bases de la prescripción de antibióticos en infecciones respiratorias. Enferm Infecc Microbiol Clin 2004; 22: 230-237.
24. Picazo, J.J., Betriu, C., Rodríguez-Avial, I., Culebras, E., Gómez, M., Grupo VIRA. Vigilancia de resistencias a los antimicrobianos: Estudio VIRA 2004. Enferm Infecc Microbiol Clin 2004; 22: 517-525.
25. Tucker, R., Rhudy, J., Hom, R., Hunt, B., Cyganowski, M. Safety and efficacy of cefditoren in acute exacerbations of chronic bronchitis. En: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canadá, 2000; 495.
26. Chow, J., Russell, M., Volk, S., Chou, C. Efficacy of cefditoren pivoxil versus amoxicillin/clavulanate in acute maxillary sinusitis. En: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000; 495.
27. Gooch, W., Marsh, D., Stickler, T., Hunt, B. Cefditoren is safe and effective treatment for streptococcal pharyngitis. En: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canadá, 2000; 495.
28. Fogarty, C.M., Cyganowski, M., Palo, W.A., Hom, R.C., Craig, W.A. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: A multicenter, prospective, randomized, investigator-blinded, parallel-group study. Clin Ther 2002; 24: 1854-1870.
29. Van Zyl, L., le Roux, J.G., LaFata, J.A. y cols. Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: Results of a multicenter, prospective, randomized, double-blind study. Clin Ther 2002; 24: 1840-1853.
30. Wellington, K., Curran, M.P. Spotlight on cefditoren pivoxil in bacterial infections. Treat Respir Med 2005; 4: 149-152.
31. Wellington, K., Curran, M.P. Cefditoren pivoxil: A review of its use in the treatment of bacterial infections. Drugs 2004; 64: 2597-2618.
32. Balbisi, E.A. Cefditoren, a new aminothiazolyl cephalosporin. Pharmacotherapy 2002; 22: 1278-1293.
33. Guay, D.R. Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin. Clin Ther 2001; 23: 1924-1937.
34. FDA/IDSA. Guidelines for the evaluation of anti-infective products. Clin Infect Dis 1992; 15 (Suppl. 1).
35. Karlowsky, J.A., Critchley, I.A., Draghi, D.C., Jones, M.E., Thornsberry, C., Sahm, D.F. Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis. Diagn Microbiol Infect Dis 2002; 42: 53-58.
36. Soriano, F., Granizo, J.J., Coronel, P. y cols. Antimicrobial susceptibility of Haemophilus influenzae, Haemophilus parainfluenzae and Moraxella catarrhalis isolated from adult patients with respiratory tract infections in four southern European countries. The ARISE project. Int J Antimicrob Agents 2004; 23: 296-299.
37. Karlowsky, J.A., Jones, M.E., Draghi, D.C., Critchley, I.A., Thornsberry, C., Sahm, D.F. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. Diagn Microbiol Infect Dis 2002; 42: 59-64.
38. Thornsberry, C., Karlowsky, J.A., Kelly, L.J. y cols. Comparative activity of cefditoren and other oral beta-lactams against nonpneumococcal streptococci. Chemotherapy 2001; 47: 332-343.
39. Soriano, F., Granizo, J.J., Fernandez-Roblas, R. y cols. Antimicrobial susceptibilities of Streptococcus pyogenes isolated from adult patients with respiratory tract and skin and soft tissue infections in four southern European countries. J Chemother 2003; 15: 293-295.
40. Spangler, S.K., Jacobs, M.R., Appelbaum, P.C. Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other beta-lactams. J Antimicrob Chemother 1997; 39: 141-148.
41. Clark, C.L., Nagai, K., Dewasse, B.E. y cols. Activity of cefditoren against respiratory pathogens. J Antimicrob Chemother 2002; 50: 33-41.
42. Martínez-Beltrán, J., Cantón, R., Coronel, P. y cols. Cefditoren (ME1206) antimicrobial profile in a multicenter study. En: 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando 1994; 51.
43. Johnson, D.M., Biedenbach, D.J., Beach, M.L., Pfaller, M.A., Jones, R.N. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Microbiol Infect Dis 2000; 37: 99-105.
44. Li, J.T., Hou, F., Lu, H., Li, T.Y., Li, H. Phase I clinical trial of cefditoren pivoxil (ME 1207): Pharmacokinetics in healthy volunteers. Drugs Exp Clin Res 1997; 23: 145-150.
45. Jones, R.N., Biedenbach, D.J., Croco, M.A., Barrett, M.S. In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1998; 31: 573-578.
46. Ficha Técnica de Spectracef. http://sinaem.agemed.es:83/ presentacion/principal.asp.
47. Alcaide, F., Linares, J., Pallarés, R. y cols. In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother 1995; 39: 2243-2247.
48. Nagai, K., Davies, T.A., Jacobs, M.R., Appelbaum, P.C. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother 2002; 46: 1273-1280.